Stock DVAX DYNAVAX TECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
11.25 USD +2.09% Intraday chart for Dynavax Technologies Corporation +0.18% -19.53%
Jul. 01 Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Defensive Index CI
Jul. 01 Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Value-Defensive Index CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Defensive Index
CI
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Value-Defensive Index
CI
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to Russell 2000 Growth-Defensive Index
CI
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
AQ
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
MT
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
PR
Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
CI
Transcript : Dynavax Technologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 04:00 PM
Dynavax to Present at Upcoming Investor Conferences
PR
Dynavax Technologies Corporation Reappoints Ernst & Young LLP as Independent Registered Public Accounting Firm
CI
Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data
MT
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA
DJ
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
RE
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
PR
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S
CI
Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024
Dynavax Technologies: Q1 Earnings Snapshot
AQ
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M
MT
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
PR
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DVAX Stock
  4. News Dynavax Technologies Corporation